

TEST CHANGE

Malignancy Risk Assessment, Pelvic Mass, OVA1 Plus

3002309, OVA1 PLUS

Specimen Requirements:

Patient Preparation: **Testing should not be performed on patients 17 years of age or younger.**

Collect: Serum **separator tube** ~~Separator Tube~~ (SST).

Specimen Preparation: Transfer 2.2 mL serum to an ARUP **standard transport tube** ~~Standard Transport Tube~~. (Min: 1.1 mL)

Transport Temperature: Frozen. Also acceptable: Refrigerated.

Unacceptable Conditions:

Remarks: Menopausal **s** ~~Status~~ required at time of ordering.

Stability: Ambient: Unacceptable; Refrigerated: 8 days; Frozen: 9 weeks

Methodology: Electrochemiluminescent Immunoassay (**ECLIA**) / Fixed-Rate-Time Nephelometry

Note: OVA1 Biomarkers: CA-125 II, **a** ~~A~~polipoprotein A1 (Apo A-1), **b** ~~B~~eta-2 **m** ~~M~~icroglobulin (B2M), **t** ~~T~~ransferrin, and **p** ~~P~~realbumin.

OVERA Biomarkers: Apolipoprotein A1 (Apo A-1), HE4 (**human epididymis** ~~Human Epididymis~~ protein 4), CA-125 II, FSH (**follicle stimulating hormone** ~~Follicle Stimulating Hormone~~), and **t** ~~T~~ransferrin.

CPT Codes: 81503

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

By Report

Deleted Cells